Selling translational research: Is science a value-neutral autonomous enterprise?

American Journal of Bioethics

Volumn 8, Issue 3, 2008, Pages 52-54

  Master, Zubin ^a   Özdemir, Vural ^b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ECONOMICS; EMBRYO RESEARCH; ETHICS; FINANCIAL MANAGEMENT; HUMAN; MEDICAL RESEARCH; NOTE; ORGANIZATION AND MANAGEMENT; RESEARCH ETHICS; STANDARD; STEM CELL; UNITED STATES;

BIOMEDICAL RESEARCH; EMBRYO RESEARCH; ETHICS, RESEARCH; HUMANS; RESEARCH SUPPORT AS TOPIC; STEM CELLS; UNITED STATES;

EID: 45849119474     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265160802109413     Document Type: Note

References (10)

1. Calvert, J. 2000. What is special about "basic research." Presented at Demarcation Socialised Conference, University of Cardiff, Cardiff, Wales, August 25-27, 2000.
2. Caulfield, T. 2004. Biotechnology and the popular press: Hype and the selling of science. Trends in Biotechnology 22(7): 337-339.
3. Emanuel, E. J., Wendler, D., and Grady, C. 2000. What makes clinical research ethical? Journal of the American Medical Association 283(20): 2701-2711.
4. Freedman, B. 1987. Scientific value and validity as ethical requirements for research: A proposed explication. IRB 9(6): 7-10.
5. Hedgecoe, A. M. 2003. Terminology and the construction of scientific disciplines: The case of pharmacogenomics. Science, Technology and Human Values 28(4): 513-537.
6. Maienschein, J., Sunderland, M., Ankeny R. A., and Robert, J. S. 2008. The ethos and ethics of translational research. American Journal of Bioethics 8(3): 43-51.
7. Master, Z., and Williams-Jones, B., 2007. The global HLA banking of embryonic stem cells requires further scientific justification. American Journal of Bioethics 7(8): 45-46.
8. Master, Z., McLeod, M., and Mendez, I. 2007. Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson's disease. Journal of Medical Ethics 33(3): 169-173.
9. Olivier, C., Williams-Jones, B., Mikalsson, B., and Özdemir, V. 2008. Personalized medicine, bioethics and social responsibilites: Rethinking the pharmaceutical industry to remedy in equities in patient care and international health. Current Pharmacogenomics and Personalized Medicine 6(2).
10. Özdemir, V., and Godard, B. 2007. Evidence-based management of nutrigenomics expectations and ELSIs. Pharmacogenomics 8(8): 1051-1062.